VEGFA and colorectal carcinoma: Additionally, FMT demonstrates significant improvements in survival rates and safety in a Phase II clinical trial that combines anti‐VEGF therapy with tislelizumab and fruquintinib for the treatment of refractory metastatic MSS CRC [140].